Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study

Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study

Background Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but come with high costs. Alternative ICI dosing strategies could reduce costs without losing efficacy. However, clinical efficacy data are lacking.Methods In this retrospective cohort trial, consecutive patients wit...

Full description

Saved in:
Bibliographic Details
Main Authors: Egbert F Smit, Willemijn S M E Theelen, Michiel M Smeenk, Vincent van der Noort, Jeroen M A Hendrikx, Hanieh Abedian Kalkhoran
Format: Article
Language:English
Published: BMJ Publishing Group 2025-02-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/2/e010065.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items